Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum

Canada NewsWire October 22, 2015

Resverlogix Announces Voting Results

Canada NewsWire September 30, 2015

Resverlogix Provides Research and Development Update in New York City

PR Newswire September 29, 2015

Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases

PR Newswire September 24, 2015

Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference

PR Newswire September 10, 2015

Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor

Canada NewsWire August 31, 2015

Resverlogix CEO Donald McCaffrey Interviewed by The Life Sciences Report

Marketwired August 27, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015